LIBRETTO-432 is a phase III study, evaluating 3 years of selpercatinib (a RET TKI) versus placebo after definitive locoregional treatment (surgery or radiotherapy) in participants with stage IB-IIIA RET fusion-positive NSCLC. This evidence concerns the gene RET and non-small cell lung carcinoma.